secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001213900-26-050249
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Therapeutics closes 9.66M-share offering at $72.50; prelim cash $496M
---------------------------------------------------------------------------

- Oruka completed underwritten public offering of 9,660,000 shares of common stock at $72.50 per share, raising gross proceeds of approximately $700 million.
- Underwriters have a 30-day option to purchase up to an additional 1,449,000 shares at the public offering price.
- Preliminary estimate of cash, cash equivalents, and investments as of March 31, 2026 is approximately $496 million.
- Offering closed April 30, 2026; underwriting agreement dated April 28, 2026 with Leerink, TD, Goldman Sachs, Stifel, Guggenheim.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390026050249/0001213900-26-050249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390026050249/ea0288461-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-050249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer